25例套细胞淋巴瘤患者诊断时与标准免疫化疗失败后克隆演变的测序分析
该研究对25例套细胞淋巴瘤患者在诊断时和标准免疫化疗失败后首次复发时进行全外显子组测序,分析变异与拷贝数变异。结果显示复发时每例患者突变数均值显著增加(复发34 vs 诊断27),TP53变异等位基因频率从0.35升至0.76,CDKN2A/B缺失最常见,LRP1B失活被确定为复发的新潜在驱动因素。
要点
- 诊断时和复发时最常见的变异基因包括TP53、ATM、KMT2D、CCND1、SP140和LRP1B。
- 复发时每例患者突变数均值显著增加(复发34 vs 诊断27),TP53变异等位基因频率从0.35升至0.76。
- 复发时新检出的LRP1B基因突变与更高的突变负荷相关,LRP1B失活被确定为MCL复发的新潜在驱动因素。
核心结论
- 数据提示复发时检测到的耐药MCL克隆在诊断时已存在,并经治疗选择。
- 观察到DNA损伤应答通路(TP53和CDKN2A/B)遗传畸变富集及MCL异质性显著增加。
- LRP1B失活被确定为MCL复发的新潜在驱动因素。
研究设计与样本
- 对25例套细胞淋巴瘤患者在诊断时和标准免疫化疗失败后首次复发时进行全外显子组测序分析。
主要发现
- 诊断时和复发时最常见的变异涉及6个基因:TP53、ATM、KMT2D、CCND1、SP140和LRP1B。
- 诊断时和复发时最常见的拷贝数变异包括TP53和CDKN2A/B缺失及PIK3CA扩增。
- 每例患者突变数均值在复发时(34)较诊断时(27)显著增加。
- 复发时新检出的最常见变异为LRP1B基因突变,与更高的突变负荷相关。
- TP53变异等位基因频率从诊断时0.35升至复发时0.76;预测拷贝数变异的频率和长度在复发时显著增加,CDKN2A/B缺失最常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our knowledge of genetic aberrations, that is, variants and copy number variations (CNVs), associated with mantle cell lymphoma (MCL) relapse remains limited. A cohort of 25 patients with MCL at diagnosis and the first relapse after the failure of standard immunochemotherapy was analyzed using whole-exome sequencing. The most frequent variants at diagnosis and at relapse comprised six genes: TP53, ATM, KMT2D, CCND1, SP140, and LRP1B. The most frequent CNVs at diagnosis and at relapse included TP53 and CDKN2A/B deletions, and PIK3CA amplifications. The mean count of mutations per patient significantly increased at relapse (n = 34) compared to diagnosis (n = 27). The most frequent newly detected variants at relapse, LRP1B gene mutations, correlated with a higher mutational burden. Variant allele frequencies of TP53 variants increased from 0.35 to 0.76 at relapse. The frequency and length of predicted CNVs significantly increased at relapse with CDKN2A/B deletions being the most frequent. Our data suggest, that the resistant MCL clones detected at relapse were already present at diagnosis and were selected by therapy. We observed enrichment of genetic aberrations of DNA damage response pathway (TP53 and CDKN2A/B), and a significant increase in MCL heterogeneity. We identified LRP1B inactivation as a new potential driver of MCL relapse.
引用
- Karolová J, Kazantsev D, Svatoň M, et al. Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy. Am J Hematol. 2023. PMID: 37605345. doi:10.1002/ajh.27044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。